Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Phathom Pharmaceuticals

Phathom Pharmaceuticals (NASDAQ: PHAT) insider transactions

In the twelve months to 10 November 2026, executives and directors of Phathom Pharmaceuticals reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Phathom Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 October 2026Narula SanjeevChief Financial & Bus. OfficerShares withheld for tax−13,485$6.78214,718Form 4
3 September 2026Breedlove Robert CharlesPrincipal Accounting OfficerShares withheld for tax−460$9.0559,465Form 4
14 July 2026Breedlove Robert CharlesPrincipal Accounting OfficerShares withheld for tax−1,555$11.0459,925Form 4
22 May 2026Parikh AsitDirectorGift−28,000—24,122Form 4
22 May 2026Parikh AsitDirectorGift+28,000—148,500Form 4
20 May 2026Parikh AsitDirectorOption exercise+17,500$4.9552,122Form 4
19 May 2026Schroeder Theodore RDirectorGrant or award+24,122—45,122Form 4
19 May 2026Karbe FrankDirectorGrant or award+24,122—91,622Form 4
19 May 2026Cola Michael FDirectorGrant or award+24,122—63,920Form 4
19 May 2026Fields HeidiDirectorGrant or award+24,122—54,122Form 4
19 May 2026Stenhouse MarkDirectorGrant or award+24,122—54,122Form 4
19 May 2026Topper James NDirectorGrant or award+24,122—66,718Form 4
19 May 2026Parikh AsitDirectorGrant or award+24,122—34,622Form 4
10 March 2026Parikh AsitDirectorGift−40,000—10,500Form 4
10 March 2026Parikh AsitDirectorGift+40,000—120,500Form 4
27 February 2026Breedlove Robert CharlesPrincipal Accounting OfficerGrant or award+13,000—60,068Form 4
27 February 2026Breedlove Robert CharlesPrincipal Accounting OfficerGrant or award+2,790—62,858Form 4
27 February 2026Breedlove Robert CharlesPrincipal Accounting OfficerShares withheld for tax−964$12.5661,894Form 4
27 February 2026Breedlove Robert CharlesPrincipal Accounting OfficerShares withheld for tax−414$12.5661,480Form 4
10 February 2026Basta Steven LPresident and CEOGrant or award+12,362—379,592Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Phathom Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.